EN DE
Watch Beijing Enterprises Medical and Health Industry Group Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beijing Enterprises Medical and Health Industry Group Ltd (2389) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Beijing Enterprises Medical and Health Industry Group Ltd stock HK$0.07, price HK$0.08, that is 7.0% below the price, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN KYG0957Q1082

BE Beijing Enterprises Medical and Health Industry Group Ltd logo Thin data Nov 10, 2026

Beijing Enterprises Medical and Health Industry Group Ltd

2389 · HK

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value HK$0.0716 · Fairly valued 
Quality 42/100 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 5y +1.0 %/yr in HKD) 
Revenue last quarter 61% below a year ago. 
Loss-making · -93.3% net margin (TTM) 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Beijing Enterprises Medical and Health Industry Group Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.1450 HK$0.0600 Fair Value HK$0.0716 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.0600 – HK$0.1450 · fair‑value band HK$0.0589 – HK$0.0843 · the HK$0.0770 price screens above the HK$0.0716 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 4 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Beijing Enterprises Medical and Health Industry Group in your weekly email

Every Wednesday you see whether Beijing Enterprises Medical and Health Industry Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Health (Holdings) Limited, an investment holding company, provides medical, health, and geriatric care related services and products in the People's Republic of China.

Show moreShow less

It engages in the investment and operation of general health industrial park; sports and health sector; and incubator projects; sports businesses, which includes construction and operation of stadiums for winter sports; and investment in the field of the biotechnology, pharmaceutical, medical services, and medical travel.

The company also provides investment management consulting services; and engages in trading geriatric care related furniture. In addition, it is involved in medical and logistics related property development activities.

The company was formerly known as Beijing Enterprises Medical and Health Industry Group Limited and changed its name to Beijing Health (Holdings) Limited in June 2021. Beijing Health (Holdings) Limited was founded in 1995 and is headquartered in Cheung Sha Wan, Hong Kong.

Stock analysis

Beijing Enterprises Medical and Health Industry Group Ltd (2389) currently trades at HK$0.0770, while our estimate is HK$0.0716, so the stock looks roughly fairly valued today (gap 7.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.0589 (bear) to HK$0.0843 (bull), the price of HK$0.0770 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.

Beijing Enterprises Medical and Health Industry Group Ltd reported revenue of HK$157M in FY2025 versus HK$204M in FY2021, a compound −6.3%/yr. Reported net income was −HK$101M in FY2025.

Key figures

Market cap HK$467M (≈ $59.5M) Micro · P/S ratio 4.10 · Net margin −64.2% · Return on equity −6.6% · Return on assets (EBIT) −3.6% (5-year average) · Operating margin −155% · Revenue (TTM) HK$111M · Revenue growth (YoY) −60.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −7%, 2389 screens richer than that median.

Fair Value

Bear HK$0.0589 Fair Value HK$0.0716 Bull HK$0.0843
Price HK$0.0770 · Downside -7.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 39
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 54
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−88.3% (2020) → −63.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 2389, get fair value alerts →

Compare Beijing Enterprises Medical and Health Industry Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside −7.0% · Below median
Profitability
Return on assets −4.8% · Bottom 25%
Net margin (12 months) −93.3% · Bottom 25%
Operating margin (12 months) −154.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −60.5% · Bottom 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.28× · Cheapest 25%
P/S (12 months) 4.21× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)24 · sector 34
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 31
HEALTH (low debt)100 · sector 90
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 2389
DaVita Inc DVA $174.56 $218.90 +25% vs 2389
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 2389
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 2389
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 2389
The Ensign Group ENSG $188.41 $140.09 −26% vs 2389
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 2389
Fresenius SE FRE €53.62 €34.77 −35% vs 2389
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 2389
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 2389

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Enterprises Medical and Health Industry Group Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beijing Enterprises Medical and Health Industry Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2389

Frequently asked questions

Is Beijing Enterprises Medical and Health Industry Group Ltd (2389) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.0716 versus a price of HK$0.0770, about 7% lower (fairly valued).
What is the fair value of 2389?
Our estimate for Beijing Enterprises Medical and Health Industry Group Ltd is HK$0.0716 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.0770.
What is the quality score of 2389?
Beijing Enterprises Medical and Health Industry Group Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Our calculated price target is the estimate of HK$0.0716 (as of Nov 10, 2026). Cautious scenario HK$0.0589, optimistic scenario HK$0.0843. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Beijing Enterprises Medical and Health Industry Group Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.0716, about 7% lower versus a price of HK$0.0770 (fairly valued). Cautious scenario HK$0.0589, optimistic scenario HK$0.0843. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Beijing Enterprises Medical and Health Industry Group Ltd reported trailing-twelve-month revenue of about HK$111M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Enterprises Medical and Health Industry Group Ltd it is HK$0.0716 per share (as of Nov 10, 2026), against a price of HK$0.0770.
Is Beijing Enterprises Medical and Health Industry Group Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2389 trades above its calculated fair value: price HK$0.0770, fair value HK$0.0716, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2389?
No. The price is what the market pays today (HK$0.0770); the fair value is what the company's own numbers justify (HK$0.0716). For Beijing Enterprises Medical and Health Industry Group Ltd the two are HK$0.0054 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Enterprises Medical and Health Industry Group Ltd worth?
The market values Beijing Enterprises Medical and Health Industry Group Ltd at about HK$467M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.0770; our models calculate a fair value of HK$0.0716 per share.
What do the bullish and bearish scenarios say about 2389?
Our models span a range for Beijing Enterprises Medical and Health Industry Group Ltd: cautious scenario HK$0.0589, base HK$0.0716, optimistic HK$0.0843 per share (as of Nov 10, 2026, price HK$0.0770). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Balance-sheet figures for Beijing Enterprises Medical and Health Industry Group Ltd (as of Nov 10, 2026): return on equity −6.6%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 2389 from its 52-week high?
Beijing Enterprises Medical and Health Industry Group Ltd trades at HK$0.0770, about 8% below its 52-week high of HK$0.0840 and 28% above the low of HK$0.0600 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0716 is for.
Which stocks are comparable to Beijing Enterprises Medical and Health Industry Group Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Enterprises Medical and Health Industry Group Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.0770, calculated fair value HK$0.0716 (−7%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Beijing Enterprises Medical and Health Industry Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The closing price on Nov 13, 2026 was HK$0.0770. Our estimate is HK$0.0716, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Enterprises Medical and Health Industry Group Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Beijing Enterprises Medical and Health Industry Group Ltd

How large is the market capitalisation of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The market capitalisation of Beijing Enterprises Medical and Health Industry Group Ltd is HK$467M (≈ $59.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The price-to-sales ratio of Beijing Enterprises Medical and Health Industry Group Ltd is 4.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The net margin of Beijing Enterprises Medical and Health Industry Group Ltd is −64.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The return on equity (ROE) of Beijing Enterprises Medical and Health Industry Group Ltd is −6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
On an EBIT basis the return on assets of Beijing Enterprises Medical and Health Industry Group Ltd is −3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The operating margin of Beijing Enterprises Medical and Health Industry Group Ltd is −155% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Revenue at Beijing Enterprises Medical and Health Industry Group Ltd is down 60.5% versus a year earlier (3y avg −1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beijing Enterprises Medical and Health Industry Group Ltd (2389) generate?
The free cash flow of Beijing Enterprises Medical and Health Industry Group Ltd is −HK$18.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beijing Enterprises Medical and Health Industry Group Ltd (2389) hold?
Beijing Enterprises Medical and Health Industry Group Ltd holds more cash than debt, HK$26.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beijing Enterprises Medical and Health Industry Group Ltd in the live analysis

One click puts Beijing Enterprises Medical and Health Industry Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.